CLCN3 and glioma: ClC-3 has also been demonstrated to participate in cisplatin resistance by regulating the Akt pathway and the autophagy process of glioma cells [170] or to promote the decreased answer to different compounds by regulating the overexpression of MDR1 by NF-κB and p65 signalling [171].